Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    10X Genomics Inc (TXG) Insider Trading Activity

    Healthcare • Health Information Services • 1,259 employees

    10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

    Total Value

    -$473,487.61

    Total Shares

    26,132

    Average Trade Value

    -$59,185.95

    Most Active Insider

    Saxonov Serge

    Total Activity: $258,065

    Largest Single Transaction

    $152,053

    by Saxonov Serge on Aug 22, 2024

    30-Day Activity

    1 Transaction

    Volume: 12,000 shares
    Value: $14,400

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Chief Executive Officer
    Dec 23, 2024 12,000 $14,400 884,574 (+1.4%) Exercise/Conversion
    Chief Executive Officer
    Nov 22, 2024 6,693 $91,612 872,574 (-0.8%) Sale
    See Remarks
    Nov 22, 2024 5,807 $79,485 339,897 (-1.7%) Sale
    Aug 30, 2024 19,002 $0 19,002 (+100.0%) Grant
    See Remarks
    Aug 22, 2024 4,351 $98,027 345,704 (-1.3%) Sale
    Chief Executive Officer
    Aug 22, 2024 6,749 $152,053 882,467 (-0.8%) Sale
    Aug 22, 2024 2,961 $66,710 143,242 (-2.1%) Sale
    Jul 31, 2024 21,691 $0 21,691 (+100.0%) Grant